Torrent Pharma reports strong Q2 FY26 growth, completes NCD redemption

Torrent Pharmaceuticals reported a 14% year-over-year increase in Q2 FY26 revenues to ₹3,302 crores and a 30% rise in net profit after tax to ₹591 crores. For the half year, revenues reached ₹6,480 crores, up 13%, with net profit after tax growing 25% to ₹1,139 crores. Operating EBITDA for Q2 FY26 also saw a 15% increase to ₹1,083 crores. The company highlighted strong performance in India, with revenues up 12% to ₹1,820 crores, and significant growth in the US (26% to ₹337 crores) and Brazil (21% to ₹318 crores).

The company also announced the redemption of non-convertible debentures (NCDs) worth ₹100 crores out of a total ₹500 crores (ISIN: INE685A07124) on November 7, 2025. Additionally, Torrent Pharmaceuticals disclosed progress on its definitive agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited, with regulatory approvals received from South Africa and India, subject to modifications, and a SEBI Observation on Draft Letter of Offer. An audio recording of the analysts' call discussing these results has been made available.